Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes

Pediatric Diabetes
Torben BiesterHanne Haahr

Abstract

Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of long-acting insulin degludec and short-acting insulin aspart. This open-label, Phase 1 study aimed to determine the pharmacodynamic and pharmacokinetic properties of IDegAsp in children (6-11 yr), adolescents (12-17 yr), and adults (18-65 yr) with type 1 diabetes mellitus (T1DM). Thirty-eight subjects received single subcutaneous IDegAsp dosing (0.5 U/kg) immediately before a standardized liquid meal (17.3 g carbohydrates/100 mL; adjusted for body weight) followed by plasma glucose (PG) and pharmacokinetic blood sampling for 36 and 57 h, respectively. There were no apparent differences between age groups in PG lowering effect (AUCPG   baseline,0-6 h,meal,SD ), maximum PG excursion (ΔPGmax,meal,SD ), or maximum PG concentration (PGmax,meal,SD ) after the standardized meal. Estimated ratios (ERs) for total exposure (AUCIAsp,0-12 h,SD ) and maximum concentration (Cmax,IAsp,SD ) of IAsp in IDegAsp were children/adults, 1.69 (95% confidence interval, CI: 1.02; 2.80) and 1.66 (95% CI: 1.10; 2.51); adolescents/adults, 1.14 (95% CI: 0.76; 1.69) and 1.16 (95% CI: 0.84; 1.61). ERs for total exposure (AUCIDeg,0-∞,SD ) and maximum concentration (Cmax,IDeg,SD ) of IDeg ...Continue Reading

References

Sep 19, 2003·The New England Journal of Medicine·Gregory L KearnsRalph E Kauffman
Apr 28, 2005·Diabetes Care·UNKNOWN Workgroup on Hypoglycemia, American Diabetes Association
Sep 6, 2007·Endocrine Reviews·S Edwin FinebergAlan S Krasner
Jan 30, 2009·Pediatric Diabetes·Denis Daneman
Jan 28, 2010·Diabetes Care·Mark PeyrotLuther B Travis
Jun 4, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Tim HeiseHanne Haahr
Jun 18, 2014·Diabetes Care·Jane L ChiangUNKNOWN Type 1 Diabetes Sourcebook Authors
Sep 3, 2014·Clinical Pharmacokinetics·Hanne Haahr, Tim Heise

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.